Total Payments
$50,944
2024 Payments
$5,113
Companies
86
Transactions
1,657
Medicare Patients
7,179
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$22,048 (43.3%)
Other$20,448 (40.1%)
Consulting$7,235 (14.2%)
Travel$761.03 (1.5%)
Education$451.02 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $22,048 | 1,629 | 43.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,448 | 10 | 40.1% |
| Consulting Fee | $7,235 | 4 | 14.2% |
| Travel and Lodging | $761.03 | 2 | 1.5% |
| Education | $451.02 | 12 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $24,137 | 199 | $0 (2024) |
| Janssen Biotech, Inc. | $5,546 | 161 | $0 (2024) |
| Ultragenyx Pharmaceutical Inc. | $3,800 | 1 | $0 (2020) |
| PFIZER INC. | $2,558 | 230 | $0 (2024) |
| ABBVIE INC. | $1,905 | 181 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,696 | 128 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,379 | 123 | $0 (2024) |
| Edap Technomed Inc | $735.00 | 3 | $0 (2024) |
| UCB, Inc. | $676.13 | 44 | $0 (2024) |
| Genentech USA, Inc. | $670.57 | 55 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,113 | 209 | Janssen Biotech, Inc. ($2,043) |
| 2023 | $2,620 | 189 | GlaxoSmithKline, LLC. ($346.41) |
| 2022 | $1,982 | 135 | ABBVIE INC. ($366.37) |
| 2021 | $2,101 | 169 | AbbVie Inc. ($372.21) |
| 2020 | $6,303 | 155 | Ultragenyx Pharmaceutical Inc. ($3,800) |
| 2019 | $26,039 | 268 | Amgen Inc. ($21,602) |
| 2018 | $2,627 | 233 | PFIZER INC. ($481.56) |
| 2017 | $4,157 | 299 | PFIZER INC. ($683.89) |
All Payment Transactions
1,657 individual payment records from CMS Open Payments — Page 1 of 67
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Immunology | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $9.12 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $1.09 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $26.65 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.33 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: RESPIRATORY | ||||||
| 11/27/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $7.45 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $27.45 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $19.00 | General |
| 11/13/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Dermatology | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.09 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $1.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $5.22 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: Immunology | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.98 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,881 | 16,458 | $3.5M | $518,179 |
| 2022 | 30 | 1,777 | 15,222 | $3.3M | $489,065 |
| 2021 | 29 | 1,823 | 14,890 | $3.5M | $531,744 |
| 2020 | 29 | 1,698 | 13,941 | $2.9M | $437,699 |
Total Patients
7,179
Total Services
60,511
Medicare Billing
$2.0M
Procedure Codes
120
All Medicare Procedures & Services
120 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 556 | 2,097 | $1.5M | $218,695 | 14.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 61 | 6,060 | $609,212 | $111,889 | 18.4% |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | Office | 2023 | 50 | 5,424 | $289,370 | $40,264 | 13.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 172 | 472 | $266,911 | $34,274 | 12.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 147 | 147 | $138,334 | $19,984 | 14.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 29 | 138 | $121,157 | $16,712 | 13.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 38 | 182 | $88,470 | $11,943 | 13.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 58 | $58,937 | $8,873 | 15.1% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 176 | 775 | $41,818 | $7,211 | 17.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 44 | 44 | $32,802 | $6,257 | 19.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 49 | $27,489 | $4,839 | 17.6% |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | Office | 2023 | 25 | 32 | $22,821 | $4,473 | 19.6% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 68 | 120 | $37,386 | $3,744 | 10.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 24 | 66 | $15,127 | $3,596 | 23.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 24 | 34 | $24,891 | $3,570 | 14.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 37 | $19,098 | $2,903 | 15.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 77 | 160 | $12,944 | $2,016 | 15.6% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 12 | 18 | $9,394 | $1,993 | 21.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $15,232 | $1,986 | 13.0% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 27 | 43 | $16,330 | $1,955 | 12.0% |
| 20551 | Injection into tendon at attachment to bone or muscle | Office | 2023 | 30 | 65 | $21,979 | $1,748 | 8.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 23 | 23 | $8,197 | $1,654 | 20.2% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 12 | 18 | $9,022 | $1,513 | 16.8% |
| 20605 | Aspiration and/or injection of fluid from medium joint | Office | 2023 | 20 | 31 | $10,812 | $1,450 | 13.4% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 62 | 173 | $5,017 | $1,036 | 20.7% |
About Dr. Michael Gross, MD
Dr. Michael Gross, MD is a Rheumatology healthcare provider based in Paramus, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1386701654.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Gross, MD has received a total of $50,944 in payments from pharmaceutical and medical device companies, with $5,113 received in 2024. These payments were reported across 1,657 transactions from 86 companies. The most common payment nature is "Food and Beverage" ($22,048).
As a Medicare-enrolled provider, Gross has provided services to 7,179 Medicare beneficiaries, totaling 60,511 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 120 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Paramus, NJ
- Active Since 01/03/2007
- Last Updated 02/05/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1386701654
Products in Payments
- Prolia (Biological) $12,930
- EVENITY (Biological) $9,573
- Cryvista (Drug) $3,800
- SIMPONI ARIA (Biological) $2,583
- TREMFYA (Drug) $2,543
- XELJANZ (Drug) $1,512
- Enbrel (Biological) $1,213
- COSENTYX (Biological) $942.51
- BENLYSTA (Biological) $793.50
- RINVOQ (Biological) $681.27
- LYRICA (Drug) $658.26
- Cimzia (Drug) $637.19
- TALTZ (Drug) $532.55
- ORENCIA (Biological) $511.94
- COSENTYX (Drug) $431.87
- KEVZARA (Drug) $392.26
- TRELEGY ELLIPTA (Drug) $377.95
- Rituxan (Biological) $295.59
- UBRELVY (Drug) $290.73
- Rasuvo (Drug) $272.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.